The target is to reduce its workforce to less than 5,000 from a level of 5,800 at the end of 2024, said chief executive ...

Hemlibra (emicizumab), the only treatment currently available for haemophilia A via the NHS that doesn't require an ...

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

President Donald Trump has given leading pharma manufacturers a 60-day deadline to come up with a most favoured nation (MFN) ...

The recent move to introduce an “Amazon-style” prescription tracking in the NHS App is a crucial first step. People want ...

When Tidmarsh was appointed to CDER, the FDA emphasised his academic and clinical credentials – including his role as ...

The foundational model could also assist Google and partner Samsung in an ongoing rivalry with Apple, currently the leader in ...

At ASCO 2025, Actuate gave an oral presentation on positive Phase 2 combination data for elraglusib, highlighting its ...

From trade associations to medtech innovators and biotech start-ups, here’s a comprehensive look at the latest boardroom ...

GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen ...

"For decades, bureaucrats and entrenched interests buried health data and blocked patients from taking control of their ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...